Jakub Svoboda, MD
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-179
3400 Civic Center Boulevard
Philadelphia, PA 19104
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-179
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-614-1846
Fax: 215-615-5888
Fax: 215-615-5888
Education:
B.A. (Biology)
Mercyhurst College (Erie, PA), 1994.
M.D. (Medicine)
Yale University School of Medicine, 2000.
Permanent linkB.A. (Biology)
Mercyhurst College (Erie, PA), 1994.
M.D. (Medicine)
Yale University School of Medicine, 2000.
Description of Research Expertise
My research interests focus on improving outcomes in patients with lymphomas using novel agents and immune based therapies. Most recently I have been involved in a trial using chimeric antigen receptor (CAR) T cells armored with the capacity to secrete interleukin 18 in efforts to enhance their activity and expansion. I serve as principal investigator of the first-in-human trial that is using the armored CAR developed by Dr. Carl June in patients with relapsed/refractory B-cell lymphomas. I have also been involved in collaborative work with our translational scientists which may allow us to find new therapeutic targets for cellular therapies.Description of Clinical Expertise
I have expertise in treating all subtypes of lymphomas and CLL/SLL.Selected Publications
Jakub Svoboda, Daniel J Landsburg, James Gerson, Sunita D Nasta, Stefan K Barta, Elise A Chong, Michael Cook, Noelle V Frey, Joanne Shea, Amanda Cervini, Amy Marshall, Megan Four, Megan M Davis, Julie K Jadlowsky, Anne Chew, Edward Pequignot, Vanessa Gonzalez, Julia Han Noll, Luca Paruzzo, Juliana Rojas-Levine, Gabriela Plesa, John Scholler, Donald L Siegel, Bruce L Levine, David L Porter, Saba Ghassemi, Marco Ruella, Andrew Rech, Rachel M Leskowitz, Joseph A Fraietta, Wei-Ting Hwang, Elizabeth Hexner, Stephen J Schuster, Carl H June: Enhanced CAR T-cell therapy for lymphoma after previous failure. New England Journal of Medicine. Massachusetts Medical Society, 392(18): 1824-1835, May 2025.Jakub Svoboda, Steven M Bair, Daniel J Landsburg, Sunita Dwivedy Nasta, Sarah J Nagle, Stefan K Barta, Nadia Khan, Joanne Filicko-O'Hara, Sameh Gaballa, Lauren Strelec, Elise Chong, Sheryl Mitnick, Terease S Waite, Cara King, Hatcher Ballard, Matthew Youngman, James Gerson, John P Plastaras, Amit Maity, Agata M Bogusz, Stacy S Hung, Hisae Nakamura, Reza Nejati, Christian Steidl, Megan Lim, Marco Ruella, Stephen J Schuster: Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. Haematologica 106(6): 1705 -1713, June 2021.
Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH.: Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med 377(26): 2545-2554, Dec 28 2017.
Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I, Suhoski MM, Melenhorst JJ, Loudon B, Mato AR, Nasta SD, Landsburg DJ, Youngman MR, Levine BL, Porter DL, June CH, Schuster SJ.: Non-viral RNA chimeric antigen receptor modified T cells in patients with Hodgkin lymphoma. Blood 132(10): 1022-1026, Sep 6 2018.
Jackson T. Bowers, Jacob Anna, Steven M. Bair, Kaitlin Annunzio, Narendranath Epperla, Jerrin Joy Pullukkara, Sameh Gaballa, Michael A. Spinner, Shuning Li, Marcus R. Messmer, Joseph Nguyen, Emily C. Ayers, Charlotte B. Wagner, Boyu Hu, Mengyang Di, Scott F. Huntington, Fateeha Furqan, Nirav N. Shah, Christina Chen, Hatcher J. Ballard, Mitchell E. Hughes, Elise A. Chong, Sunita D. Nasta, Stefan K. Barta, Daniel J. Landsburg, Jakub Svoboda: Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort. Blood Advances 7(21): 6630–6638, November 2023.
Ruan J, Martin P, Shah B, Schuster SJ, Smith,SM, Furman RR, Christos P, Rodriguez A, Svoboda J, Lewis J, Katz O, Coleman M, Leonard, JP: Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphoma. New England Journal of Medicine 373(19): 1835-44, Nov 5 2015.
G Ghilardi, EA Chong, J Svoboda, P Wohlfarth, SD Nasta, S Williamson, JD Landsburg, JN Gerson, SK Barta, R Pajarillo, J Myers, AI Chen, L Schachter, R Yelton, HJ Ballard, A Hodges Dwinal, S Gier, D Victoriano, E Weber, E Napier, A Garfall, DL Porter, U Jäger, RT Maziarz, M Ruella, SJ Schuster: Bendamustine is Safe and Effective for Lymphodepletion Before Tisagenlecleucel in Patients with Refractory or Relapsed Large B-Cell Lymphomas. Annals of Oncology Jun 2022.
Julie K Jadlowsky, Elizabeth O Hexner, Amy Marshall, Stephan A Grupp, Noelle V Frey, James L Riley, Elizabeth Veloso, Holly McConville, Walter Rogal, Cory Czuczman, Wei-Ting Hwang, Yimei Li, Rachel M Leskowitz, Olivia Farrelly, Jayashree Karar, Shannon Christensen, Julie Barber-Rotenberg, Avery Gaymon, Naomi Aronson, Wendy Bernstein, Jan Joseph Melenhorst, Aoife M Roche, John K Everett, Sonja A Zolnoski, Alexander G McFarland, Shantan Reddy, Angelina Petrichenko, Emma J Cook, Carole Lee, Vanessa E Gonzalez, Kathleen Alexander, Irina Kulikovskaya, Ángel Ramírez-Fernández, Janna C Minehart, Marco Ruella, Saar I Gill, Stephen J Schuster, Adam D Cohen, Alfred L Garfall, Payal D Shah, David L Porter, Shannon L Maude, Bruce L Levine, Donald L Siegel, Anne Chew, Stephen McKenna, Lester Lledo, Megan M Davis, Gabriela Plesa, Friederike Herbst, Edward A Stadtmauer, Pablo Tebas, Amanda DiNofia, Andrew Haas, Naomi B Haas, Regina Myers, Donald M O’Rourke, Jakub Svoboda, Janos L Tanyi, Richard Aplenc, Jeffrey M Jacobson, Andrew H Ko, Roger B Cohen, Carl H June, Frederic D Bushman, Joseph A Fraietta: Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nature Medicine. Nature Publishing Group US, 31: 1134-1144, January 2025.
P Armand, S Rodig, V Melnichenko, C Thieblemont, K Bouabdallah, G Tumyan, M Özcan, S Portino, L Fogliatto, MD Caballero, J Walewski, Z Gulbas, V Ribrag, B Christian, GF Perini, G Salles, J Svoboda, J Zain, S Patel, PH Chen, AH Ligon, J Ouyang, D Neuberg, R Redd, A Chatterjee, A Balakumaran, R Orlowski, M Shipp, and PL Zinzani: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. J Clin Oncol. 37(34): 3291-3299, Dec 1 2019.
Elise A Chong, Cécile Alanio, Jakub Svoboda, Sunita D Nasta, Daniel J Landsburg, Simon F Lacey, Marco Ruella, Siddharth Bhattacharyya, E John Wherry, Stephen J Schuster: Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood, The Journal of the American Society of Hematology 139(7): 1026-1038, Feb 2022.
Miguel-Angel Perales, Larry D Anderson Jr, Tania Jain, Saad S Kenderian, Olalekan O Oluwole, Gunjan L Shah, Jakub Svoboda, Mehdi Hamadani: Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy Elsevier, 28(9): 546-559, September 2022 Notes: Electronically published June 26, 2022.
Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xaiver AC, Okal R, Kanate AS, Ghosh N, Kharfan-Dabaja MA, Strelec L, Hamadani M, Fenske TS, Calzada O, Cohen JB, Chavez J, and Svoboda, J.: R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol 180(4): 534-544, Feb 2018.
Bair SM, Mato A, Svoboda J.: Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm. Clin Lymphoma Myeloma Leuk 18(6): 380-391, Jun 2018.
Frigault MJ, Maziarz RT, Park JH, Lazaryan A, Shah NN, Svoboda J, Lekakis LJ, Reshef R, Phillips CL, Burke L, Lei J, Pratta M, Morariu-Zamfir R, DiPersio JF.: Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 Study. Blood Mar 2025.